Racial disparities in access after regulatory surveillance of benzodiazepines

Archives of Internal Medicine

Volumn 166, Issue 5, 2006, Pages 572-579

  Pearson, Sallie Anne ^a,b   Soumerai, Stephen ^a   Mah, Connie ^a   Zhang, Fang ^a   Simoni Wastila, Linda ^c   Salzman, Carl ^d   Cosler, Leon E ^e   Fanning, Thomas ^f   Gallagher, Peter ^f   Ross Degnan, Dennis ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^d MASSACHUSETTS MENTAL HEALTH CENTER   (United States)

^e ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^f NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE;

ADULT; ARTICLE; BIPOLAR DISORDER; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG SURVEILLANCE PROGRAM; FEMALE; HEALTH CARE ACCESS; HEALTH PROGRAM; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAID; OUTCOMES RESEARCH; PERIODIC MEDICAL EXAMINATION; POPULATION RESEARCH; POVERTY; PRESCRIPTION; PRIORITY JOURNAL; RACE DIFFERENCE; SCHIZOPHRENIA; SEIZURE; SEX DIFFERENCE; TREATMENT WITHDRAWAL; UNITED STATES;

ADULT; AGED; ANTI-ANXIETY AGENTS; ANXIETY; BENZODIAZEPINES; DRUG UTILIZATION; ETHNIC GROUPS; FEMALE; HUMANS; LEGISLATION, DRUG; MALE; MEDICAID; MIDDLE AGED; NEW YORK; PRESCRIPTIONS, DRUG; PROGRAM EVALUATION;

EID: 33644982968     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.166.5.572     Document Type: Article

References (40)

1. Chen J, Rathore SS, Radford MJ, Wang Y, Krumholz HM. Racial differences in the use of cardiac catheterization after acute myocardial infarction. N Engl J Med. 2001;344:1443-1449.
2. Schneider EC, Zaslavsky AM, Epstein AM. Racial disparities in the quality of care for enrollees in Medicare managed care. JAMA. 2002;287:1288-1294.
3. Gornick ME, Eggers PW, Reilly TW, et al. Effects of race and income on mortality and use of services among Medicare beneficiaries. N Engl J Med. 1996;335:791-799.
4. Ayanian JZ, Udvarhelyi IS, Gatsonis CA, Pashos CL, Epstein AM. Racial differences in the use of revascularization procedures after coronary angiography. JAMA. 1993;269:2642-2646.
5. Ayanian JZ, Cleary PD, Weissman JS, Epstein AM. The effect of patients' preferences on racial differences in access to renal transplantation. N Engl J Med. 1999;341:1661-1669.
6. Bach PB, Cramer LD, Warren JL, Begg CB. Racial differences in the treatment of early-stage lung cancer. N Engl J Med. 1999;341:1198-1205.
7. Klabunde CN, Potosky AL, Harlan LC, Kramer BS. Trends and black/white differences in treatment for nonmetastatic prostate cancer. Med Care. 1998;36:1337-1348.
8. Freeman HP, Payne R. Racial injustice in health care. N Engl J Med. 2000;342:1045-1047.
9. Whittle J, Conigliaro J, Good CB, Lofgren RP. Racial differences in the use of invasive cardiovascular procedures in the Department of Veterans Affairs medical system. N Engl J Med. 1993;329:621-627.
10. Fillenbaum GG, Horner RD, Hanlon JT, Landerman LR, Dawson DV, Cohen HJ. Factors predicting change in prescription and nonprescription drug use in a community-residing black and white elderly population. J Clin Epidemiol. 1996;49:587-593.
11. Khandker RK, Simoni-Wastila LJ. Differences in prescription drug utilization and expenditures between Blacks and Whites in the Georgia Medicaid population. Inquiry. 1998;35:78-87.
12. Fillenbaum GG, Hanlon JT, Corder EH, Ziqubu-Page T, Wall WEJ, Brock D. Prescription and nonprescription drug use among black and white community-residing elderly. Am J Public Health. 1993;83:1577-1582.
13. Swartz M, Landerman R, George LK, Melville ML, Blazer D, Smith K. Benzodiazepine anti-anxiety agents: prevalence and correlates of use in a southern community. Am J Public Health. 1991;81:592-596.
14. Blazer D, Hybels C, Simonsick E, Hanlon JT. Sedative, hypnotic, and antianxiety medication use in an aging cohort over ten years: a racial comparison. JAmGeriatr Soc. 2000;48:1073-1079.
15. Morrison RS, Wallenstein S, Natale DK, Senzel RS, Huang LL. "We don't carry that": failure of pharmacies in predominantly nonwhite neighborhoods to stock opioid analgesics. N Engl J Med. 2000;342:1023-1026.
16. Shader RI, Greenblatt DJ, Balter MB. Appropriate use and regulatory control of benzodiazepines. J Clin Pharmacol. 1991;31:781-784.
17. Mort EA, Weissman JS, Epstein AM. Physician discretion and racial variation in the use of surgical procedures. Arch Intern Med. 1994;154:761-767.
18. Schulman KA, Berlin JA, Harless W, et al. The effect of race and sex on physicians' recommendations for cardiac catheterization. N Engl J Med. 1999;340:618-626.
19. Simoni-Wastila L, Tompkins C. Balancing diversion control and medical necessity: the case of prescription drugs with abuse potential. Subst Use Misuse. 2001;36:1275-1296.
20. US Department of Justice. A closer look at state prescription monitoring programs. Available at: http://www.deadiversion.usdoj.gov/pubs/program/ rx_monitor. Accessed March 17, 2003.
21. American Psychiatric Association Task Force on Benzodiazepine Dependency. Benzodiazepine Dependency, Toxicity and Abuse. Washington, DC: American Psychiatric Association; 1990.
22. Soumerai SB, Simoni-Wastila L, Singer C, et al. Lack of relationship between longterm use of benzodiazepines and escalation to high dosages. Psychiatr Serv. 2003;54:1006-1011.
23. Salzman C. Treatment of anxiety. In: Clinical Geriatric Psychopharmacology. 2nd ed. Baltimore, Md: Williams & Wilkins; 1992:189-212.
24. Sheikh JI, Salzman C. Anxiety in the elderly: course and treatment. Psychiatr Clin North Am. 1995;18:871-883.
25. Ross-Degnan D, Simoni-Wastila L, Brown J, et al. A controlled study of the effects of state surveillance on indicators of problematic and non-problematic benzodiazepine use in a Medicaid population. Int J Psychiatry Med. 2004;34:103-123.
26. McNutt LA, Coles FB, McAuliffe T, et al. Impact of regulation on benzodiazepine prescribing to a low income elderly population, New York State. J Clin Epidemiol. 1994;47:613-625.
27. Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S. Payment restrictions for prescription drugs under Medicaid: effects on therapy, cost and equity. N Engl J Med. 1987;317:550-556.
28. Soumerai SB, Ross-Degnan D, Avorn J, McLaughlin T, Choodnovskiy I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med. 1991;325:1072-1077.
29. First Databank. National Drug Data File Plus. Available at: http://www.firstdatabank.com/knowledge_bases/nddf_plus/. Accessed December 12, 2005.
30. Food and Drug Administration. National Drug Code Directory. Available at: http://www.fda.gov/cder/ndc/database/default.htm. Accessed December 12, 2005.
31. Federspiel CF, Ray WA, Schaffner W. Medicaid records as a valid data source: the Tennessee experience. Med Care. 1976;14:166-172.
32. Bright RA, Avorn J, Everitt DE. Medicaid data as a resource for epidemiologic studies: strengths and limitations. J Clin Epidemiol. 1989;42:937-945.
33. Ross-Degnan D, Soumerai SB, Fortess EE, Gurwitz JH. Examining product risk in context: market withdrawal of zomepirac as a case study. JAMA. 1993;270:1937-1942.
34. Simoni-Wastila L, Ross-Degnan D, Mah C, et al. A retrospective data analysis of the impact of the New York triplicate prescription program on benzodiazepine use in Medicaid patients with chronic psychiatric and neurologic disorders. Clin Ther. 2004;26:322-336.
35. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Impact of a Medicaid drug benefits limit on use of psychotropics and acute mental health care among schizophrenic patients. N Engl J Med. 1994;331:650-655.
36. USP DI® System: Volume 1: Drug Information for the Healthcare Professional. Greenwood Village, Colo: Thomson Micromedex; 2004.
37. International Classification of Diseases, Ninth Revision, Clinical Modification. 6th ed. Los Angeles, Calif: Practice Management Information Corp; 2000.
38. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27:299-309.
39. Gillings D, Makuc D, Siegel E. Analysis of interrupted time series mortality trends: an example to evaluate regionalized perinatal care. Am J Public Health. 1981;71:38-46.
40. SAS/ETS Users Guide, Version 6. 2nd ed. Cary, NC: SAS Institute Inc; 1993.